Yonago Acta Medica
Online ISSN : 1346-8049
ISSN-L : 0513-5710
Original Article
Pemafibrate Dramatically Ameliorated the Values of Liver Function Tests and Fibrosis Marker in Patients with Non-Alcoholic Fatty Liver Disease
Suguru IkedaTakaaki SugiharaYoshiki HoshinoYukako MatsukiTakakazu NagaharaJun-ichi OkanoSonoko KitaoYouhei FujiokaKazuhiro YamamotoHajime Isomoto
Author information

2020 Volume 63 Issue 3 Pages 188-197


Background Non-alcoholic fatty liver disease (NAFLD) is a chronic liver disease related to metabolic syndrome, which can progress to liver cirrhosis. Standard medication has not been established. Pemafibrate is a selective peroxisome proliferator-activated receptor (PPAR) α modulator. We retrospectively evaluated the efficacy of pemafibrate in patients with NAFLD.

Methods We retrospectively enrolled 17 patients (ten men, seven women; median age, 63 years; range, 27–81 years). They were all proven to have fatty liver through imaging and had little or no history of drinking (ethanol consumption of < 20 g/day for women and < 30 g/day for men). They were administered pemafibrate from October 2018 to June 2020.

Results After administration, serum triglyceride (TG) tended to be decreased (300.5 ± 22.5 to 239.5 ± 34.3 mg/dL, P = 0.06). Serum high-density lipoprotein (HDL) cholesterol and low-density lipoprotein (LDL) cholesterol levels did not change. ALT was significantly decreased (–47.4%) for six months (57.5 ± 8.8 to 30.3 ± 5.8 U/L, P < 0.01). The values of serum GGT significantly decreased (–48.7%) for sixth months (63.9 ± 10.3 to 32.8 ± 6.6 U/L, P < 0.01). Aspartate aminotransferase (AST) to platelet ratio (APRI), a fibrosis marker, also was significantly decreased in the sixth month (0.7 ± 0.1 to 0.4 ± 0.1, P < 0.05). Body mass index (BMI) and hemoglobin A1c (HbA1c) showed no significant change.

Conclusion Pemafibrate dramatically ameliorated the values of liver function tests and APRI in patients with NAFLD.

Content from these authors
© 2020 Tottori University Medical Press
Previous article Next article